We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Established in 2014, we have expanded into 5 global locations and have grown to over 100 employees.
History
- February 2014
TCB was founded
TCB commenced operations in February 2014, leasing space for its lab, office and cleanroom facilities in April 2014. The initial build was completed within 6 months.
- January 2015
TC BioPharm received MHRA approval to initiate cancer trial
TC BioPharm received a license from MHRA to produce gamma delta T cell therapy products at its clinical manufacturing facility near Glasgow, UK.
- July 2015
TC BioPharm raised £1.2 million for UK cancer trial
TC BioPharm raised equity and grant funding from Scottish Enterprise and Investing Woman.
- December 2015
Initiation of ImmuniCell® trial
This was an adaptive clinical trial for TC BioPharm’s autologous gamma delta T cell product for melanoma, lung and kidney cancer.
- January 2017
TC BioPharm raised £6.25 million
Funds raised from NIPRO and Scottish Investment Bank for further clinical development of gamma delta T cell therapies.
- August 2017
TC BioPharm granted €4 million from EU H2020 research and innovation program
The funding supported development of TC BioPharm’s clinical program of unmodified allogeneic gamma delta T cell products for the treatment of cancer in a phase 1 clinical trial.
- September 2017
TC BioPharm licensed CAR-T technology from UCL
The agreement was to progress innovative gene-modified T cell therapies capable of treating childhood and adult cancers of the blood such as acute myeloid leukemia (AML).
- December 2017
TC BioPharm partnered with bluebird bio
The companies continue to work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical trials as well as on additional hematologic and solid tumor targets.
- February 2018
TC BioPharm partnered with NIPRO
The strategic partnership co-develops a novel gamma delta CAR-T product for the treatment of cancer.
- February 2018
TC BioPharm opened first overseas office in Japan
TC BioPharm opened the new office as a foundation to expand its cell therapy business through Japan and Asia.
- May 2018
TC BioPharm partnered with Scotia Biologics
Using Scotia’s unique technology, the two companies are working on a range of cancer-targeting single-chain antibodies, each of which can be formulated to treat a specific type of cancer.
- January 2019
TC BioPharm created allogeneic cell banks for CAR-T
Via funding from H2020, TC BioPharm completes formulation of its first allogeneic gamma delta T cell bank.
- February 2019
Strategic partnership established with Trinity College Dublin
The partnership with Dublin’s Trinity College was established for in-house production of V delta 1 gamma delta T cell banks for treatment of solid tumors.
- March 2019
TC BioPharm extended space at Glasgow headquarters
TC BioPharm used the new space to facilitate manufacturing of GMP lentivirus, a key starting material in the process for creating their pioneering CAR-T cancer therapies.
- April 2019
Initiated phase 1 allogeneic gamma delta T cell trial
The trial, for treatment of patients suffering from Acute Myeloid Leukemia (AML), is being conducted at the Institute of Hematology and Blood Transfusion (ÚHKT) in Prague, Czech Republic.
- May 2019
TC BioPharm opened offices in London and Leiden
Continued growth saw TC BioPharm expand office space in London, UK and Leiden, The Netherlands.